AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26975187 — intervention group
Group type: EXPERIMENTAL
Intervention: Task shifting interventions delivered by trained frontline health workers (Anganwadi workers and ASHA workers) for a minimum period of 18 months.
Number of subjects: 120
Study 26975187 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care or no intervention).
Number of subjects: 120
Study 25560571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100mg plus metformin
Number of subjects: 61
Study 25560571 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 61
Study 25560571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus metformin
Number of subjects: 61
Study 23842505 — intervention group
Group type: EXPERIMENTAL
Intervention: CR® neuromodulation therapy
Number of subjects: 0
Study 23842505 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 0
Study 20863217 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine 1000 mg/day for 12 weeks
Number of subjects: 36
Study 20863217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18195111 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC2 inhibitor probenecid
Number of subjects: 0
Study 18195111 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific inhibitor verapamil
Number of subjects: 0
Study 18195111 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 inhibitor valspodar (PSC833)
Number of subjects: 0
Study 18195111 — intervention group
Group type: COMPARATOR
Intervention: Talinolol
Number of subjects: 0
Study 15928933 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at VO2peak for 5 min) in the upright position
Number of subjects: 7
Study 15928933 — intervention group
Group type: COMPARATOR
Intervention: Inactive recovery (complete rest for 5 min) in the upright position
Number of subjects: 7
Study 15928933 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (cycling at VO2peak for 5 min) in the supine position
Number of subjects: 7
Study 15928933 — intervention group
Group type: COMPARATOR
Intervention: Inactive recovery (complete rest for 5 min) in the supine position
Number of subjects: 7
Study 12571548 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 1 week
Number of subjects: 39
Study 12571548 — intervention group
Group type: COMPARATOR
Intervention: Placebo-CPAP (CPAP administered at ineffective pressure)
Number of subjects: 39
Study 10596415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria (Töpfer Bifidus) administered via nasogastral tube, initial dosage of 3 times daily 1.25 x 10(8) bifidobacteria on day 2, then 6 times daily 1.25 x 10(8) bifidobacteria on day 3 until day 21
Number of subjects: 100
Study 10596415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bifidobacteria)
Number of subjects: 100
Study 10596415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria (Töpfer Bifidus)
Number of subjects: 100
Study 8739869 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgicel Nu‐knit
Number of subjects: 60
Study 8739869 — intervention group
Group type: COMPARATOR
Intervention: Vasolene gauze
Number of subjects: 60
Study 8739869 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 60
Study 1915209 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 39
Study 1915209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7046758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin, 1 gm/day
Number of subjects: 80
Study 7046758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin, 1.5 gm/day
Number of subjects: 80
Study 7046758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7046758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin
Number of subjects: 80
Study 31479383 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory‐motor integration (AMI) intervention
Number of subjects: 12
Study 31479383 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological memory and planning (PMP) intervention
Number of subjects: 12
Study 31479383 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) intervention
Number of subjects: 12
Study 28196063 — intervention group
Group type: EXPERIMENTAL
Intervention: dCRT (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² bd on days 1-21 for four cycles)
Number of subjects: 258
Study 28196063 — intervention group
Group type: COMPARATOR
Intervention: dCRT+C (dCRT plus cetuximab 400 mg/m² on day 1 then 250 mg/m² weekly)
Number of subjects: 258
Study 28196063 — intervention group
Group type: EXPERIMENTAL
Intervention: dCRT
Number of subjects: 258
Study 28196063 — intervention group
Group type: COMPARATOR
Intervention: dCRT+C
Number of subjects: 258
Study 26398851 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg for 8 weeks
Number of subjects: 114
Study 26398851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 24230931 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning potential assessment for children with specific language impairment
Number of subjects: 64
Study 24230931 — intervention group
Group type: COMPARATOR
Intervention: Learning potential assessment for children with typical development
Number of subjects: 64
Study 21327797 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 28
Study 19743466 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 1,500mg daily
Number of subjects: 163
Study 19743466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 17942025 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% isopropyl myristate (IPM) rinse
Number of subjects: 0
Study 17942025 — intervention group
Group type: COMPARATOR
Intervention: Positive control (RID; pyrethrin 0.33%, piperonyl butoxide 4%)
Number of subjects: 0
Study 12612146 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement (272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopherol, and 400 micro g folic acid) for 90 days
Number of subjects: 77
Study 12612146 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 77
Study 11118067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 1251
Study 11118067 — intervention group
Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 1251
Study 9167147 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic gentamicin/metronidazole with gentamicin-collagen sponge (Group I)
Number of subjects: 221
Study 9167147 — intervention group
Group type: COMPARATOR
Intervention: Systemic gentamicin/metronidazole without gentamicin-collagen sponge (Group II)
Number of subjects: 221
Study 1556292 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious Cognitive-Behavioral Therapy (RCT)
Number of subjects: 59
Study 1556292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonreligious Cognitive-Behavioral Therapy (NRCT)
Number of subjects: 59
Study 1556292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastoral Counseling Treatment-as-Usual (PCT)
Number of subjects: 59
Study 1556292 — intervention group
Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 59
Study 3889361 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex sonography
Number of subjects: 229
Study 31362785 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ice cryotherapy (30 min applied twice during 1 day at an 8-h interval)
Number of subjects: 47
Study 31362785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold CO2 (2 min applied twice during 1 day at an 8-h interval)
Number of subjects: 47
Study 31362785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-treated knees (phase II)
Number of subjects: 47
Study 31362785 — intervention group
Group type: COMPARATOR
Intervention: Contralateral non-treated arthritic knees (phase II)
Number of subjects: 47
Study 28228420 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR, n = 143)
Number of subjects: 218
Study 28228420 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum control (AL, n = 75)
Number of subjects: 218
Study 25885180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool dialysate at 35.5°C
Number of subjects: 20
Study 25885180 — intervention group
Group type: COMPARATOR
Intervention: Warm dialysate at 37°C
Number of subjects: 20
Study 24088417 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation of a disease management programme (DMP) for COPD
Number of subjects: 744
Study 24088417 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation strategy (Control group)
Number of subjects: 744
Study 24088417 — intervention group
Group type: COMPARATOR
Intervention: External control group
Number of subjects: 744
Study 21418180 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐PC
Number of subjects: 201
Study 21418180 — intervention group
Group type: COMPARATOR
Intervention: C‐PC
Number of subjects: 201
Study 19638799 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM) with wound care specialist (WCS) consults (Group A)
Number of subjects: 103
Study 19638799 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly visits with WCSs (Group B)
Number of subjects: 103
Study 19638799 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care (Group C)
Number of subjects: 103
Study 16978805 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with prebiotic fructo-oligosaccharides at a concentration of 0.4 g/dL
Number of subjects: 56
Study 16978805 — intervention group
Group type: COMPARATOR
Intervention: Formula with maltodextrin as a placebo
Number of subjects: 56
Study 15547636 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 174
Study 15547636 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 174
Study 11384825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print booklets plus telephone counseling (TP+TC)
Number of subjects: 1127
Study 11384825 — intervention group
Group type: COMPARATOR
Intervention: Tailored print booklets (TP)
Number of subjects: 1127
Study 11384825 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1127
Study 10210340 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC using fixed catheter‐tip method
Number of subjects: 90
Study 10210340 — intervention group
Group type: COMPARATOR
Intervention: HAIC using conventional method
Number of subjects: 90
Study 10210340 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC without prior TACE
Number of subjects: 90
Study 10210340 — intervention group
Group type: COMPARATOR
Intervention: HAIC with prior TACE
Number of subjects: 90
Study 7843445 — intervention group
Group type: EXPERIMENTAL
Intervention: Air bubbles loaded into the transfer catheter (group I)
Number of subjects: 196
Study 7843445 — intervention group
Group type: COMPARATOR
Intervention: No air bubbles used (group II)
Number of subjects: 196
Study 2205292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplement daily for 28 days
Number of subjects: 227
Study 2205292 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 28 days
Number of subjects: 227
Study 152694 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25% aluminum chloride hexahydrate in anhydrous ethanol (ACAE)
Number of subjects: 141
Study 31305150 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified course
Number of subjects: 226
Study 31305150 — intervention group
Group type: COMPARATOR
Intervention: Traditional course
Number of subjects: 226
Study 31305150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both courses
Number of subjects: 226
Study 29127858 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic review (FT)
Number of subjects: 429
Study 29127858 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face clinic management (FC)
Number of subjects: 429
Study 26141142 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to antipsychotic monotherapy
Number of subjects: 104
Study 26141142 — intervention group
Group type: COMPARATOR
Intervention: Stay on polypharmacy
Number of subjects: 104
Study 23892681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified maize meal (soy protein, iron, vitamin A, folic acid, zinc, niacin)
Number of subjects: 308
Study 23892681 — intervention group
Group type: COMPARATOR
Intervention: Unfortified flour
Number of subjects: 308
Study 21612469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust-mite allergen
Number of subjects: 48
Study 21612469 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 48
Study 21612469 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 48
Study 21612469 — intervention group
Group type: COMPARATOR
Intervention: Albuterol followed by methacholine (control)
Number of subjects: 48
Study 19529912 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self‐advancing jejunal tube (Tiger Tube)
Number of subjects: 42
Study 19529912 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic guided jejunal tube (Freka Trelumina)
Number of subjects: 42
Study 16722829 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg primaquine with food
Number of subjects: 20
Study 16722829 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg primaquine with grapefruit juice
Number of subjects: 20
Study 16722829 — intervention group
Group type: COMPARATOR
Intervention: 30 mg primaquine in fasting state
Number of subjects: 20
Study 16722829 — intervention group
Group type: COMPARATOR
Intervention: Comparison between genders
Number of subjects: 20
Study 12790260 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group intervention
Number of subjects: 73
Study 12790260 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 73
Study 10375047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures (BMI, waist girth, WHR, sum of three skinfolds) among urban and rural boys and girls.
Number of subjects: 5518
Study 10375047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures among boys across SES tertiles.
Number of subjects: 5518
Study 10375047 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measures among girls across SES tertiles.
Number of subjects: 5518
Study 10375047 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical interactions between school year and body fatness.
Number of subjects: 5518
Study 8686522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg morphine and 2.5 mg dehydrobenzperidol (DHB) in 10 ml physiological saline
Number of subjects: 68
Study 8686522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg morphine and 0.1 mg fentanyl in 10 ml physiological saline
Number of subjects: 68
Study 8686522 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with saline only
Number of subjects: 68
Study 1905474 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil-based diet
Number of subjects: 16
Study 1905474 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil-based diet
Number of subjects: 16
Study 1905474 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 16
Study 6619578 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant leukocyte A interferon (rIFN‐alpha A) 10 X 10(6) units per day for four days
Number of subjects: 26
Study 6619578 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 6619578 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant leukocyte A interferon (rIFN‐alpha A)
Number of subjects: 26
Study 4026908 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily
Number of subjects: 18
Study 4026908 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 18
Study 30370872 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma applied in-between temporalis fascia graft and tympanic membrane remnant during underlay myringoplasty (n = 20)
Number of subjects: 40
Study 30370872 — intervention group
Group type: COMPARATOR
Intervention: Routine underlay tympanoplasty (n = 20)
Number of subjects: 40
Study 30370872 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma group (n = 20)
Number of subjects: 40
Study 30370872 — intervention group
Group type: COMPARATOR
Intervention: Routine underlay tympanoplasty group (n = 20)
Number of subjects: 40
Study 27857189 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (oral administration for 8 weeks)
Number of subjects: 82
Study 27857189 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide with KCNQ1 inhibitor
Number of subjects: 82
Study 27857189 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide in patients with CT or TT genotypes
Number of subjects: 82
Study 24075865 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy by stripping with saline injection (saline group)
Number of subjects: 86
Study 24075865 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy by stripping with vasopressin injection technique (VIT group)
Number of subjects: 86
Study 24075865 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cystectomy by stripping without injection (control group)
Number of subjects: 86
Study 22277625 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme consisting of three group educational sessions followed by one individual educational session.
Number of subjects: 141
Study 22277625 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 141
Study 20113339 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150-600 mg/day (dosed twice daily)
Number of subjects: 476
Study 18377153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Program (MLP)
Number of subjects: 0
Study 16271654 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone psychotherapy program (TPP) consisting of 8-12 telephone sessions (8 core CBT sessions and 3-4 clinical booster sessions) delivered by a master-level therapist.
Number of subjects: 0
Study 16271654 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone psychotherapy program (TPP) during maintenance-phase treatment (6-12 months).
Number of subjects: 0
Study 12499212 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 400/100 mg BID
Number of subjects: 57
Study 12499212 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir 533/133 mg BID
Number of subjects: 57
Study 12499212 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir and efavirenz IQ parameters
Number of subjects: 57
Study 12499212 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline characteristics
Number of subjects: 57
Study 10204899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 110
Study 10204899 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 110
Study 10204899 — intervention group
Group type: COMPARATOR
Intervention: 0.125% ropivacaine
Number of subjects: 110
Study 10204899 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 110
Study 8888300 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian observers discriminating male and female Caucasian faces
Number of subjects: 0
Study 8888300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oriental observers discriminating male and female Japanese faces
Number of subjects: 0
Study 8888300 — intervention group
Group type: EXPERIMENTAL
Intervention: Female observers of both races
Number of subjects: 0
Study 1794268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 584
Study 1794268 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 584
Study 1794268 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 584
Study 6575987 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice
Number of subjects: 0
Study 6575987 — intervention group
Group type: COMPARATOR
Intervention: Monofluorophosphate-sodium fluoride dentifrice
Number of subjects: 0
Study 30464128 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thrombus burden reduction therapy
Number of subjects: 46
Study 30248056 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neurofeedback cognitive training using the BRAINMEM system, comprising 24 sessions over eight weeks and three monthly booster sessions.
Number of subjects: 0
Study 30248056 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-Control group (no specific intervention details provided).
Number of subjects: 0
Study 27940785 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) clinics
Number of subjects: 19776
Study 27940785 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 19776
Study 27940785 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) clinics in suburban schools
Number of subjects: 19776
Study 27940785 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) in suburban schools
Number of subjects: 19776
Study 27940785 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) clinics in urban schools
Number of subjects: 19776
Study 27940785 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) in urban schools
Number of subjects: 19776
Study 24445833 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 4363
Study 24445833 — intervention group
Group type: COMPARATOR
Intervention: Inactivated control trivalent influenza vaccines (TIVs) containing Victoria-lineage B strain
Number of subjects: 4363
Study 24445833 — intervention group
Group type: COMPARATOR
Intervention: Inactivated control trivalent influenza vaccines (TIVs) containing Yamagata-lineage B strain
Number of subjects: 4363
Study 21916952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdenture retained by two splinted implants with bar-clip system
Number of subjects: 29
Study 21916952 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures (CDs)
Number of subjects: 29
Study 20082624 — intervention group
Group type: COMPARATOR
Intervention: Glipizide controlled-release (CR) tablets monotherapy
Number of subjects: 40